Solid Biosciences

Solid Bio hopes to fortify itself after fusing with AavantiBio, but not before axing its lead asset
Fierce Biotech
Fri, 09/30/22 - 10:58 am
Solid Biosciences
M&A
gene therapy
AavantiBio
Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events
Fierce Biotech
Tue, 05/17/22 - 10:31 pm
Duchenne Muscular Dystrophy
gene therapy
Pfizer
Sarepta Therapeutics
Genethon
Solid Biosciences
Solid Bio’s long, troubled slog through the clinic yields promising early data. Can it win back trust?
Endpoints
Mon, 03/15/21 - 11:58 pm
Solid Biosciences
gene therapy
Duchenne Muscular Dystrophy
FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial
BioSpace
Thu, 10/1/20 - 11:08 pm
Solid Biosciences
FDA
clinical trials
gene therapy
Duchenne Muscular Dystrophy
FDA keeps Solid Bio's troubled Duchenne MD gene therapy on clinical lockdown in latest setback
Endpoints
Mon, 07/27/20 - 11:05 am
Solid Biosciences
Duchenne Muscular Dystrophy
FDA
gene therapy
Solid Bio Restructures to Get Halted Gene Therapy Study Back on Track
Xconomy
Thu, 01/9/20 - 10:35 am
Solid Biosciences
gene therapy
reorganization
Duchenne Muscular Dystrophy
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Mon, 12/16/19 - 10:52 am
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity
Stat
Tue, 11/12/19 - 09:52 am
Solid Biosciences
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
SGT-001
Solid Biosciences Surges on DMD Gene Therapy Study Amendments
Yahoo/Zacks.com
Mon, 08/19/19 - 10:54 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
Solid Biosciences’ Duchenne Muscular Dystrophy Drug Has Side Effect Issues
BioSpace
Tue, 05/14/19 - 11:37 pm
Solid Biosciences
Duchenne Muscular Dystrophy
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Endpoints
Thu, 02/7/19 - 09:37 am
Solid Biosciences
clinical trials
Duchenne Muscular Dystrophy
SGT-001
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
3 Best Gene Therapy Stocks of 2018 (So Far)
Motley Fool
Thu, 07/5/18 - 11:04 am
gene therapy
FDA
Sarepta Therapeutics
Solid Biosciences
Regnxbio
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
Xconomy
Mon, 06/18/18 - 11:25 am
Duchenne Muscular Dystrophy
Solid Biosciences
Sarepta Therapeutics
SGT-001
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
CP Wire
Wed, 04/18/18 - 09:54 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
clinical trials
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
Wed, 04/18/18 - 09:40 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold
Fierce Biotech
Wed, 03/14/18 - 09:29 pm
Solid Biosciences
gene therapy
FDA
DMD
Duchenne Muscular Dystrophy
In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M
Endpoints
Tue, 01/2/18 - 07:41 pm
biotech
IPOs
PureTech
ARMO BioSciences
Menlo Therapeutics
Solid Biosciences
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences